The increase in the price target from $95 to $105 by RBC Capital suggests a positive outlook on Korro Bio's future performance. The 'Outperform' rating indicates that the analyst expects the stock to perform better than the market average, which is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.